IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Metastatic Malignant Solid Neoplasm
M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
276 Active assets in the Metastatic Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 3 | BB |
Irinotecan Incyte Corporation | Phase 3 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | BB |
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →